Company: BDRX
Filing Date: 2025-01-21
Form Type: 424B3
Source: 0001214659-25-000936
Chunk: 13

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-21
Form: 424B3
Chunk 13
---
 Notwithstanding the foregoing, in the event that (a) the Investor is the holder of any Depositary Shares on the Fixed Purchase Date that were the subject of a Fixed Purchase Notice for such Fixed Purchase Date, and (b) if within three (3) Business Days immediately following a Fixed Purchase Date, the Company issues or sells any Depositary Shares or Ordinary Share Equivalents (calculated on an as converted, as exercised basis), in each case other than pursuant to an Exempt Issuance, pursuant to which Depositary Shares may be acquired at a per share price less than the Fixed Purchase Price for such Fixed Purchase (the “ New Issuance Price”), then the Fixed Purchase Price related to that subject Fixed Purchase Notice shall be reduced to the New Issuance Price, subject to Section 2(e)(ii)hereof.

| -4- |

(x) “” means, with respect to any Fixed Purchase, VWAP Purchase or Additional VWAP Purchase made pursuant to
hereof, $1.00, which shall be appropriately adjusted for any reorganization, recapitalization, non-cash dividend, share split, reverse
share split, Depositary Share-Ordinary Share ratio change or other similar transaction and, effective upon the consummation of any such
reorganization, recapitalization, non-cash dividend, share split, reverse share split, Depositary Share-Ordinary Share ratio change or
other similar transaction, the Floor Price shall mean the lower of (i) the adjusted price and (ii) $1.00.

(y) “” means any material adverse effect on (i) the enforceability of any Transaction Document, (ii) the results of
operations, assets, business or financial condition of the Company and its Subsidiaries, taken as a whole, other than any material adverse
effect that resulted primarily from (A) any change in the United States or foreign economies or securities or financial markets in general
that does not have a disproportionate effect on the Company and its Subsidiaries, taken as a whole, (B) any change that generally affects
the industry in which the Company and its Subsidiaries operate that does not have a disproportionate effect on the Company and its Subsidiaries,
taken as a whole, (C) any change arising in connection with pandemics, earthquakes, hostilities, acts of war, sabotage or terrorism or
military actions or any escalation or material worsening of any such hostilities, acts of war, sabotage or